Notice Regarding Change in Management Structure
CMIC Holdings announced a change in its management structure effective April 1, 2026, separating supervisory and executive roles and introducing an executive officer system to strengthen governance and accelerate decision-making.
📋 Article Processing Timeline
- 📰 Published: April 2, 2026 at 01:00
- 🔍 Collected: April 1, 2026 at 16:47
- 🤖 AI Analyzed: April 21, 2026 at 08:15 (471h 27m after Collected)
We hereby announce that our company will change its management structure effective April 1, 2026, as follows.
1. Change in Management Structure
Our company will change its management structure on April 1, 2026, for the purpose of clearly separating the roles of supervision and execution and further strengthening corporate governance.
Through this change, we aim to enhance the supervisory function of the Board of Directors by inviting outside directors who possess high-level expertise in management analysis and governance, and who are well-versed in the domestic and international pharmaceutical and healthcare industries.
At the same time, we will introduce an executive officer system and delegate the authority of the President and Executive Officer to the respective unit heads of the business and corporate divisions, thereby realizing faster decision-making and clearer roles and responsibilities.
2. Board of Directors Structure (Effective April 1, 2026)
Name / Title
Keiko Oishi / Representative Director
Shunji Katayama / Director
Kazutaka Echigo / Director
Eriko Kawai / Outside Director
Christopher Alberney / Outside Director
Stephen Engen / Outside Director
Wataru Mochizuki / Auditor
3. Executive Officer Structure (Effective April 1, 2026)
[Table content truncated in original source]
1. Change in Management Structure
Our company will change its management structure on April 1, 2026, for the purpose of clearly separating the roles of supervision and execution and further strengthening corporate governance.
Through this change, we aim to enhance the supervisory function of the Board of Directors by inviting outside directors who possess high-level expertise in management analysis and governance, and who are well-versed in the domestic and international pharmaceutical and healthcare industries.
At the same time, we will introduce an executive officer system and delegate the authority of the President and Executive Officer to the respective unit heads of the business and corporate divisions, thereby realizing faster decision-making and clearer roles and responsibilities.
2. Board of Directors Structure (Effective April 1, 2026)
Name / Title
Keiko Oishi / Representative Director
Shunji Katayama / Director
Kazutaka Echigo / Director
Eriko Kawai / Outside Director
Christopher Alberney / Outside Director
Stephen Engen / Outside Director
Wataru Mochizuki / Auditor
3. Executive Officer Structure (Effective April 1, 2026)
[Table content truncated in original source]